


Pembrolizumab KEYNOTE-010

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Less serious adverse events observed



Other adjustments



Pembrolizumab KEYNOTE-010

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Locally advanced or metastatic NSCLC with PD-L1 expression  $\geq 1\%$  TPS after  $\geq 1$  prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)

Experimental Arm: Pembrolizumab

Control Arm: Docetaxel



